Last reviewed · How we verify
Breast Cancer
Approved treatments
- Paraplatin · MYLAN SEIYAKU Ltd
Carboplatin produces predominantly interstrand DNA cross-links in a cell-cycle nonspecific manner. - Tumor Tissue · Pfizer
- Talzenna · Pfizer Inc.
PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers. - PF-07850327, ARV-471, vepdegestrant · Pfizer
- Technetium Tc 99M Sestamibi · Cyclomedica
Technetium Tc 99m Sestamibi accumulates in viable myocardial tissue similar to thallous chloride TI-201, with possible mitochondrial retention. - Paraplatin · ARCAGY/ GINECO GROUP
Pipeline
- palbociclib plus letrozole · Pfizer Inc. — preclinical
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: